1. Introduction {#sec1-cancers-10-00417}
===============

There is limited differentiation in treatment guidelines between soft tissue sarcoma (STS) subtypes \[[@B1-cancers-10-00417],[@B2-cancers-10-00417]\]. However, distinct subtypes with specific characteristics are being recognized; features that distinguish subtypes include morphology, immunohistochemistry, genomics, molecular profile and clinical features \[[@B3-cancers-10-00417]\]. Identifying histology-specific treatment is important where STS subtypes are being classified and treated based on molecular and genetic characteristics as well as differential natural history and chemosensitivity \[[@B3-cancers-10-00417],[@B4-cancers-10-00417]\]. Currently, there is no systemic anti-cancer therapy approved specifically for synovial sarcoma (SS).

SS is an aggressive malignancy which accounts for approximately 5--10% of all STS \[[@B5-cancers-10-00417],[@B6-cancers-10-00417],[@B7-cancers-10-00417],[@B8-cancers-10-00417]\]. The estimated incidence of SS is 1.5 per 1,000,000 in the US and 1.4 per 1,000,000 in the UK \[[@B7-cancers-10-00417],[@B9-cancers-10-00417],[@B10-cancers-10-00417],[@B11-cancers-10-00417]\]. It is the most common non-rhabdomyosarcoma STS in children and young adults \[[@B8-cancers-10-00417]\]. Approximately one-third of SS occurs in childhood, but peak incidence is in the third decade of life \[[@B12-cancers-10-00417]\]. SS frequently arises in the extremities, but can also develop from serosal surfaces of almost any part of the body such as the pleura or pericardium \[[@B7-cancers-10-00417],[@B8-cancers-10-00417]\].

SS has unique pathologic and genomic characteristics including histologic subtypes, biphasic and monophasic, and a characteristic translocation, t(X;18)(p11.2;q11.2) \[[@B13-cancers-10-00417]\]. Other genomic characteristics such as the B-cell lymphoma 6 co-repressor (BCOR) upregulation and the immunoreaction of the nuclear tumor suppressor gene SMRRCB1/INI1 (INI1) were not found to be associated with a worse prognosis \[[@B14-cancers-10-00417],[@B15-cancers-10-00417]\]. SS is one of the most common STS subtypes to express *NY-ESO-*1; greater than 80% of synovial tumors express *NY-ESO-1*, which is associated with worse prognosis \[[@B16-cancers-10-00417],[@B17-cancers-10-00417],[@B18-cancers-10-00417],[@B19-cancers-10-00417],[@B20-cancers-10-00417]\].

There are no approved systemic therapies that target these histologic or genomic characteristics. Surgical resection is the standard treatment for localized SS, with consideration for use of neoadjuvant/adjuvant radiation and/or systemic anti-cancer therapy \[[@B7-cancers-10-00417],[@B21-cancers-10-00417]\]. Prognosis for non-metastasized patients is often favorable for tumors \<5 cm resected with adequate margins \[[@B22-cancers-10-00417]\]; local recurrence occurs in approximately 17% of patients \[[@B14-cancers-10-00417]\]. Metastatic disease is present in approximately 24% of the patients at diagnosis \[[@B14-cancers-10-00417]\]. SS is associated with local recurrence and distant metastases. Metastases occur in 50--70% of cases \[[@B23-cancers-10-00417]\]; most metastases develop in the lungs (80%), followed by bone (10%) and liver (5%) \[[@B5-cancers-10-00417]\]. Locally advanced or metastatic SS tends to be treated initially with systemic anti-cancer therapy \[[@B24-cancers-10-00417]\], however, there is no consensus regarding the most appropriate therapy regimen or sequence. The prognosis of patients with metastatic SS is limited regardless of treatment \[[@B25-cancers-10-00417]\].

Treatment decisions for SS are informed by clinical features and published data obtained from trials that enrolled multiple STS subtypes. These trials were not designed to evaluate the impact of systemic anti-cancer therapy on a specific histologic subtype. This makes it difficult to evaluate the potential benefit for a specific histology such as SS.

No systematic overview of survival outcomes achieved with systemic anti-cancer therapy across studies specific to SS currently exists. The objective was to conduct a systematic literature review (SLR) of current published data on survival outcomes and responses to systemic anti-cancer therapy in SS. This review can serve to support development of future research and inform guidelines specific to SS using currently available anti-cancer therapies.

2. Materials and Methods {#sec2-cancers-10-00417}
========================

Methodology for the SLR was consistent with recommendations published in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and by the Centre for Reviews and Dissemination \[[@B26-cancers-10-00417],[@B27-cancers-10-00417]\].

2.1. Search Strategy and Study Selection {#sec2dot1-cancers-10-00417}
----------------------------------------

The search for peer-reviewed literature was limited to studies published in 2000 or later to evaluate the effect of systemic anti-cancer therapy on SS in the modern era. The following electronic databases were searched via the OVID search portal: Embase, MEDLINE, and the Cochrane Central Register of Controlled Trials (2000 to 30 January 2018). Search strategies are provided in the [supplementary material (Table S1)](#app1-cancers-10-00417){ref-type="app"}. In addition, conference proceedings were searched for 2015--2017 for the following conferences: American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), and Connective Tissue Oncology Society (CTOS) Annual Meeting.

All abstracts and full text articles were reviewed according to the pre-specified eligibility criteria, outlined in [Table 1](#cancers-10-00417-t001){ref-type="table"}, by two independent reviewers (Reviewers: JT, KM, ZK). Any studies where the reviewers disagreed on inclusion at either selection stage were referred to a third independent reviewer for a final decision. A PRISMA flow diagram ([Figure 1](#cancers-10-00417-f001){ref-type="fig"}) was developed indicating the numbers of studies included and excluded at each stage of the review.

2.2. Data Extraction {#sec2dot2-cancers-10-00417}
--------------------

Data were captured in an Excel^®^ (Microsoft) extraction template (included in the [Supplementary Material](#app1-cancers-10-00417){ref-type="app"}) by a single reviewer and were independently validated by a second reviewer (Reviewers: Juliette Thompson, Kerstin Mueller, Zaeem Khan). Extracted data included study characteristics (study design, follow-up periods, and main inclusion/exclusion criteria), patient characteristics (mean age, sex distribution, prior therapies, disease stage, performance status, histology, and tumor size), treatment details, and efficacy endpoints (overall survival, progression-free survival, tumor response).

2.3. Data Analysis {#sec2dot3-cancers-10-00417}
------------------

Data were synthesized in tabular format; efficacy outcomes were stratified by age, histology, treatments, or by localized or advanced/metastatic disease when available in the publication. Overall survival (OS) and progression-free survival (PFS) were the primary outcomes of interest.

3. Results {#sec3-cancers-10-00417}
==========

A total of 3198 abstracts were identified in the search, and 28 met the inclusion criteria for this review ([Figure 1](#cancers-10-00417-f001){ref-type="fig"}). Of the included publications, 25 were retrospective studies reporting between 51 and 1318 SS patients, including a retrospective analysis of data from 15 clinical trials (9 Phase II, 2 Phase II/III and 4 Phase III) published between 1987 and 2015 \[[@B28-cancers-10-00417]\], and three were prospective studies (two trials \[1 phase III, 1 undefined\] and one observational study) reporting between 70 and 188 SS patients ([Table 2](#cancers-10-00417-t002){ref-type="table"}). The objectives of the included publications are listed in the [supplementary material (Table S2)](#app1-cancers-10-00417){ref-type="app"}.

Despite the majority of publications being retrospective studies, most indicated SS was histologically or pathologically confirmed in the study sample. Only four studies indicated whether immunohistochemical results were required or recommended for diagnosis \[[@B12-cancers-10-00417],[@B29-cancers-10-00417],[@B30-cancers-10-00417],[@B31-cancers-10-00417]\]. Only one study indicated classification of STS based on ICD-codes \[[@B32-cancers-10-00417]\] only; the risk of misclassification was noted \[[@B33-cancers-10-00417]\]. One publication discussed how histological review altered diagnosis for patients, 2/94 patients had been misdiagnosed \[[@B12-cancers-10-00417]\]. Details of SS diagnosis was not provided in four studies \[[@B28-cancers-10-00417],[@B34-cancers-10-00417],[@B35-cancers-10-00417],[@B36-cancers-10-00417]\].

Sixteen of 28 studies focused on localized disease \[[@B4-cancers-10-00417],[@B12-cancers-10-00417],[@B23-cancers-10-00417],[@B31-cancers-10-00417],[@B34-cancers-10-00417],[@B35-cancers-10-00417],[@B36-cancers-10-00417],[@B37-cancers-10-00417],[@B38-cancers-10-00417],[@B39-cancers-10-00417],[@B40-cancers-10-00417],[@B41-cancers-10-00417],[@B42-cancers-10-00417],[@B43-cancers-10-00417]\], 10/28 studies included both localized and metastatic disease \[[@B11-cancers-10-00417],[@B25-cancers-10-00417],[@B28-cancers-10-00417],[@B29-cancers-10-00417],[@B30-cancers-10-00417],[@B44-cancers-10-00417],[@B45-cancers-10-00417],[@B46-cancers-10-00417],[@B47-cancers-10-00417],[@B48-cancers-10-00417]\], and 2/28 studies focused on metastatic disease \[[@B49-cancers-10-00417],[@B50-cancers-10-00417]\] ([Table 1](#cancers-10-00417-t001){ref-type="table"}). Definitions of disease status were infrequently reported; generally just stating whether the population included was either localized or non-metastatic without staging information. Six studies reported disease stage at the start of the study. Details on whether patients were considered resectable were reported in 14 studies ([Table 3](#cancers-10-00417-t003){ref-type="table"}). Of the included studies, eight were conducted in North America \[[@B4-cancers-10-00417],[@B23-cancers-10-00417],[@B33-cancers-10-00417],[@B34-cancers-10-00417],[@B39-cancers-10-00417],[@B42-cancers-10-00417],[@B45-cancers-10-00417],[@B48-cancers-10-00417]\], 15 in Europe \[[@B11-cancers-10-00417],[@B25-cancers-10-00417],[@B28-cancers-10-00417],[@B29-cancers-10-00417],[@B31-cancers-10-00417],[@B35-cancers-10-00417],[@B36-cancers-10-00417],[@B37-cancers-10-00417],[@B38-cancers-10-00417],[@B40-cancers-10-00417],[@B41-cancers-10-00417],[@B43-cancers-10-00417],[@B46-cancers-10-00417],[@B47-cancers-10-00417],[@B49-cancers-10-00417],[@B50-cancers-10-00417]\], two in Japan \[[@B30-cancers-10-00417],[@B44-cancers-10-00417]\], and two were multi-regional \[[@B12-cancers-10-00417],[@B51-cancers-10-00417]\]. Length of study follow-up ranged from 12.3 months \[[@B51-cancers-10-00417]\] to 11.4 years (137 months) \[[@B38-cancers-10-00417]\] for localized disease and from 51 months \[[@B44-cancers-10-00417]\] to 78 months \[[@B45-cancers-10-00417]\] for metastatic disease ([Table 2](#cancers-10-00417-t002){ref-type="table"}).

Baseline characteristics of patients were heterogeneous ([Table 3](#cancers-10-00417-t003){ref-type="table"}): median age ranged from 12 \[[@B36-cancers-10-00417],[@B41-cancers-10-00417]\] to 42.5 years \[[@B29-cancers-10-00417]\] and 26.7% \[[@B34-cancers-10-00417]\] to 63% were female \[[@B42-cancers-10-00417]\]. Monophasic tumors accounted for 18% \[[@B31-cancers-10-00417]\] to 85% \[[@B42-cancers-10-00417]\] and biphasic tumors for 15% \[[@B42-cancers-10-00417]\] to 77% \[[@B31-cancers-10-00417]\] of tumors. Primary tumors in the upper extremities ranged from 13% \[[@B34-cancers-10-00417]\] to 37% \[[@B4-cancers-10-00417]\] and in the lower extremities from 33% \[[@B34-cancers-10-00417]\] to 85% \[[@B4-cancers-10-00417]\].

Radiotherapy was received by 12% to 97% of patients in the localized setting \[[@B4-cancers-10-00417],[@B36-cancers-10-00417]\], only one study reported radiotherapy use in metastatic patients (58%) \[[@B49-cancers-10-00417]\]. Where reported, radiotherapy was received at a median dose of 45--65 Gy. \[[@B34-cancers-10-00417],[@B36-cancers-10-00417],[@B39-cancers-10-00417],[@B41-cancers-10-00417],[@B47-cancers-10-00417]\]. Those receiving systemic anti-cancer therapy ranged from 14% for adult patients with localized SS \[[@B34-cancers-10-00417]\] to 100% in the metastatic setting \[[@B49-cancers-10-00417]\]. In the localized disease setting, between 51% \[[@B41-cancers-10-00417]\] and 100% \[[@B34-cancers-10-00417],[@B35-cancers-10-00417],[@B37-cancers-10-00417],[@B46-cancers-10-00417]\] of patients underwent surgery ([Table 3](#cancers-10-00417-t003){ref-type="table"}).

Our study focused on outcomes with the use of systemic anti-cancer therapy. Only four of the included publications (Vlenterie \[[@B28-cancers-10-00417]\], Ferrari \[[@B47-cancers-10-00417]\], Gronchi \[[@B51-cancers-10-00417]\], Sanfillipo \[[@B49-cancers-10-00417]\]) reported outcomes by the type of systemic anti-cancer therapy. Other publications simply reported the proportion of patients receiving systemic anti-cancer therapy for which outcomes were reported.

PFS and OS outcomes were assessed using various definitions, imaging methods and follow-up periods at varying time points between the individual studies ([Table 4](#cancers-10-00417-t004){ref-type="table"}). Among 11 studies reporting PFS, the endpoint was defined in eight studies as the time between diagnosis, study registration, or randomization and the latest date of event-free follow-up, disease progression, recurrence, or death. No definition of PFS was provided in three studies. OS was reported by 20 studies, of which only nine provided a definition as the time between diagnosis, study registration, randomization, or treatment initiation and the reported death date or last known date of follow-up. Most publications reported proportions of surviving patients at specific time points. Only six publications reported median follow-up durations for survival outcomes.

3.1. Localized Disease {#sec3dot1-cancers-10-00417}
----------------------

Two studies reported treatment responses in patients with localized disease, one of which was response to surgery rather than systemic anti-cancer therapy, so was not considered relevant \[[@B36-cancers-10-00417]\]. Al-Hussaini reported that one of 10 adult patients achieved a partial response and in the pediatric population two of 5 patients achieved response using the RECIST criteria (one partial, one complete) \[[@B34-cancers-10-00417]\].

Among the publications reporting survival data for patients with localized disease, three-year PFS rates were reported by Ferrari (2015), ranging from 91.7% to 91.2% \[[@B12-cancers-10-00417]\]. Three-year OS among the same patient subgroups were both 100%. Reports of five-year PFS ranged from 26% \[[@B37-cancers-10-00417]\] to 80.7% \[[@B12-cancers-10-00417]\] and five-year OS from 40% \[[@B37-cancers-10-00417]\] to 90.7% \[[@B12-cancers-10-00417]\]. Ten-year PFS was reported by two studies and ranged between 53% \[[@B39-cancers-10-00417],[@B47-cancers-10-00417]\] and 89% \[[@B41-cancers-10-00417]\]. Ten-year OS was reported by six studies and ranged from 51% \[[@B45-cancers-10-00417]\] to 78% \[[@B41-cancers-10-00417]\] ([Table 4](#cancers-10-00417-t004){ref-type="table"}).

Generally in studies of localized disease, patient outcomes were only reported for the whole study cohort and by disease stage at diagnosis ([Table 4](#cancers-10-00417-t004){ref-type="table"}). Typically, grade 3 disease was associated with a shorter PFS and OS compared to grade 1 or 2 disease. Deshmukh reported a five-year PFS of 70% for grade 1 or 2 disease versus 55% for grade 3 disease \[[@B45-cancers-10-00417]\]. Similarly, Kreig reported a five-year OS of 97% for grade 2 patients compared to 15% for grade 3 patients \[[@B38-cancers-10-00417]\]. Vining observed a significant risk of mortality in patients with grade 3 disease compared to grade 1 or 2 (hazard ratio: 2.32, 95% confidence interval: 1.46--3.67; *p* \< 0.001) \[[@B33-cancers-10-00417]\]. In addition to the overall estimates of PFS reported (81.9% at 3 years), Ferrari provided results for patients in low (IRS group I, ≤5 cm tumor: 91.7% at 3 years) and intermediate (IRS group I, \>5 cm tumor and all IRS group II: 91.2% at 3 years) risk groups \[[@B12-cancers-10-00417]\]. Similarly, Al-Hussaini provided results for the adult (five-year PFS: 68.3%) and pediatric (five-year PFS: 74.9%) populations separately as well as combined (five-year PFS: 69.3%) \[[@B34-cancers-10-00417]\].

Two retrospective studies reported OS for localized disease. Median OS in patients that underwent resection/amputation was 40.1 months (3.3 years) for patients treated between 1955 and 1999, all of which were classified as FNCLCC grade 3 \[[@B31-cancers-10-00417]\]. Median OS in Italiano was 136 months (11.3 years) for patients with completely resected localized SS; 47.2% of these patients were classified as FNCLCC grade 3 \[[@B35-cancers-10-00417]\].

3.2. Mixed Population (Locally Advanced and Metastatic Disease) {#sec3dot2-cancers-10-00417}
---------------------------------------------------------------

Four studies of mixed populations reported response to treatment, which was generally a combination doxorubicin (Dox) + Iifosfamide (Ifo). In Ferrari, overall response was 56% in patients receiving Dox or epirubicin+Ifo compared to 31% in patients treated with "other" chemotherapy as any line of treatment \[[@B47-cancers-10-00417]\]. In Setsu, 20% of patients treated with primarily Ifo-based adjuvant or second-line therapy achieved a partial response \[[@B44-cancers-10-00417]\].

Spurrell examined responses using radiology reports on patients treated from 1978--2003. Response to chemotherapy was recorded via retrospective viewing of radiology reports (most reports using Response Evaluation Criteria In Solid Tumors \[RECIST\], but historical reports using World Health Organization \[WHO\] criteria). They found that out of 92 patients that received first-line chemotherapy for advanced disease (metastatic, local recurrence not amenable to complete excision or primary tumor not amenable to excision), 38 had a response (Dox + Ifo: *n* = 18/30; Dox: *n* = 6/25; Ifo: *n* = 4/25).

However, the details for those responses are not provided and 35 of the 92 patients had metastectomies which may have confounded response assessments \[[@B25-cancers-10-00417]\]. Median OS for the total population in this study was 22 months \[[@B25-cancers-10-00417]\].

Vlenterie reported a retrospective analysis of outcomes for cohorts of SS subjects enrolled across 15 prospective clinical trials in first-line systemic treatment for advanced STS published between 1987 and 2015. Treatment response using WHO or RECIST ranged between 21.5% and 33.3%; complete response was highest in CYVADIC (cyclophosphamide, vincristine, adriamycin, DTIC) treated patients (10%, *n* = 30), however, a similar complete response rate was observed for the larger cohort available for Dox + Ifo (*n* = 112, CR: 6.3%) \[[@B28-cancers-10-00417]\]. The publication reported 27.8% of SS with treatment responses compared to 18.8% for other STS \[[@B28-cancers-10-00417]\].

One-year PFS outcomes to first-line treatment were reported in locally advanced and/or metastatic disease by Vlenterie. One-year PFS was highest in patients who received CYVADIC (23.3%) \[[@B28-cancers-10-00417]\]. The longest median PFS was 7.5 months in the Dox + Ifo treatment group. Greatest one-year OS outcomes were also achieved in the Dox + Ifo subgroup (66.3%) but the longest median duration for OS was 15.8 months in the CYVADIC group, reported in a trial published in 1995 \[[@B28-cancers-10-00417]\].

The most consistently reported time point for PFS and OS in mixed population studies was at five years. Ferrari included patients with locally advanced (*n* = 40/271) or metastatic disease (*n* = 16/271) and reported a five-year PFS of 36.8% for all patients; ten-year PFS was 29.8% \[[@B47-cancers-10-00417]\]. Five year OS across four studies ranged from 52% in an SS unspecified population reported by Corey \[[@B48-cancers-10-00417]\] to 69.8% in a mixed population receiving surgery and chemotherapy consisting primarily of Dox + Ifo in Takenaka \[[@B30-cancers-10-00417]\]. Deshmukh reported a ten-year OS of 42% in all patients in the cohort, which included localized (*n* = 99/135), locally recurrent (*n* = 9/135) and metastatic (*n* = 27/135) patients \[[@B45-cancers-10-00417]\].

3.3. Metastatic Disease {#sec3dot3-cancers-10-00417}
-----------------------

Five retrospective studies reported treatment response in patients with metastatic disease. In Sanfilippo, a retrospective analysis of advanced SS patients in Italy, all patients (*n* = 61) treated with trabectedin assessed were evaluable for response according to the RECIST criteria; 15% achieved a partial response, and 35% had stable disease \[[@B49-cancers-10-00417]\]. In a population where 89% had surgery in plus systemic anti-cancer therapy five-year OS was 10% \[[@B46-cancers-10-00417]\], and in a population where 92.5% had surgery and 21.3% had radiotherapy in addition to systemic anti-cancer therapy five-year OS was 0% \[[@B30-cancers-10-00417]\]. In a population where 90% received surgery and 71% received radiotherapy in addition to systemic anti-cancer therapy, 15% of patients were alive at ten years \[[@B45-cancers-10-00417]\].

METASARC is a prospective observational analysis of SS (*n* = 188) ([Table 5](#cancers-10-00417-t005){ref-type="table"}). It was not captured in the literature search due to the absence of a SS term in title or abstract, but included here due to its importance. The analysis consisted of metastatic patients, 80% of whom were treated with systemic anti-cancer therapy and 49% underwent a locoregional treatment of the metastasis: five-year OS was 7.14% \[[@B50-cancers-10-00417]\], consistent with observations reported in retrospective studies in this literature review.

4. Discussion {#sec4-cancers-10-00417}
=============

The number of STS subtypes recognized as distinct entities is growing, including myxoid liposarcoma \[[@B62-cancers-10-00417],[@B63-cancers-10-00417]\], undifferentiated pleomorphic sarcoma \[[@B4-cancers-10-00417]\], and malignant peripheral nerve sheath tumor \[[@B64-cancers-10-00417]\]. Subtype-specific treatments demonstrating superior outcomes include eribulin in liposarcoma \[[@B65-cancers-10-00417]\], gemcitabine plus dacarbazine in leiomyosarcoma \[[@B66-cancers-10-00417]\], and trabectedin in both liposarcoma and leiomyosarcoma \[[@B67-cancers-10-00417],[@B68-cancers-10-00417]\]. Recently pembrolizumab showed responses in patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma \[[@B69-cancers-10-00417]\], also; both gemcitabine alone and gemcitabine-docetaxel appeared to be active in leiomyosarcoma \[[@B70-cancers-10-00417]\].

SS is a distinct subtype needing a tailored approach for management and further research; the identification of a specific genetic alteration suggests targeted therapy could be of greater value than conventional therapy \[[@B15-cancers-10-00417]\]. Due to a lack of data, no consensus guidelines exist regarding the optimal agents, sequencing or number of cycles of systemic anti-cancer therapy for SS. As a rare tumor type it lacks funding to conduct an adequately powered randomized study to address the question of which agents and sequencing are optimal to treat this disease.

SS is frequently identified as a chemosensitive STS; in 1994 an original publication of 13 patients with recurrent or metastatic disease treated with high dose ifosfamide reported a response in all patients \[[@B71-cancers-10-00417]\]. A retrospective review of advanced SS patients using RECIST found Dox + Ifo achieved responses at a higher rate compared to single agent doxorubicin or ifosfamide; however these results may have been confounded by the use of metastectomies \[[@B25-cancers-10-00417]\]. There are no published prospective clinical trials that document SS as being more chemosensitive than the broad group of STS \[[@B72-cancers-10-00417]\].

Few studies included linked specific anti-cancer therapy regimens with survival outcomes; most aggregated survival outcomes into a single estimate of efficacy for the studied population, rather than outcomes being reported independently by each agent or for the enrolled SS cohort. This makes it difficult to determine which anti-cancer therapy may be driving the survival benefit or outcomes for the SS cohort reported in the studies included in this review.

A recent study by Wang calculated an aggregate five-year OS of localized and metastatic SS patients from the SEER registry for the years 2002 to 2013 to be 60.5% regardless of line of therapy \[[@B7-cancers-10-00417]\]. Almost half of the 12 studies (5/12) we identified in this review that presented five-year OS for mixed populations of localized and advanced stage patients reported proportions of survivors that were within 5 percent points of this value (range: −8.5% to +11.5%). The SEER study also showed significantly shorter survival for patients with distant compared to localized stage SS, with median OS not reached among those with localized disease, and median OS with distant disease of under 20 months \[[@B7-cancers-10-00417]\].

A limitation observed in the results of the SLR was the restricted number of prospective studies identified for inclusion. There were two reasons for this: first, the eligibility criteria of the review required that at least 50 SS patients were reported in a study. Secondly, the design of prospective studies in STS, which frequently recruit numerous sarcoma histologies, meaning that data for SS are available either only for a small cohort of patients (\<50 SS participants), or that the data from the SS patients are incorporated in the overall STS results. In the conduct of this systematic review with a specific focus on SS, results reported in this way were not captured. Thus, the current available evidence can only be based on studies including all STS histological subtypes. As knowledge of the differences and molecular heterogeneity of the specific subtypes increases, the development of clinical trials is moving towards study designs for specific histologic subtypes. In current practice, data from prospective STS clinical trials are used to inform treatment practice for SS.

Beyond the limitations of the review, the data reported in this SLR also have multiple limitations that should be considered when evaluating the reported results. They include but are not limited to the following: the majority of patients were treated prior to either RECIST v1.0 or v1.1 and the definition of responses are not always provided nor systematically applied; imaging methods were not consistent nor is it known if trained radiologists evaluated the response assessments; there is selection bias as to which systemic anti-cancer therapy was administered and the dose intensity is not reported; there was heterogeneity of patients treated in studies including locally advanced and metastatic disease; the majority of reported results are from retrospective or observational studies and as such there is no reporting of how data was censored or if data was source verified.

In order to mitigate the limitations which led to the paucity of data from the SLR, we evaluated data from trials which combined multiple histologies. From this we compiled prospective studies of systemic anti-cancer treatments that included a cohort of fewer than 50 SS patients as part of the STS enrolled population, and the key survival results they provided. Due to the focus on systemic treatment, the majority of these identified prospective studies (7/10) had recruited patients with metastatic disease. One study focused on locally advanced and metastatic \[[@B54-cancers-10-00417]\] and two on relapsed or refractory disease \[[@B53-cancers-10-00417],[@B54-cancers-10-00417]\].

The number of SS patients included in the prospective studies ranged from 7 to 38 ([Table 5](#cancers-10-00417-t005){ref-type="table"}). Only two of the prospective studies reported outcomes beyond one year, which are compared to the outcomes presented in the studies identified in our SLR. Three-year PFS and OS was 56.3% and 81.3% for pediatric and adolescent patients treated with neoadjuvant vincristine, Dox + Ifo for locally advanced disease \[[@B54-cancers-10-00417]\].

Across all relapsed/refractory and metastatic studies, median OS ranged from 6.7 to 13.4 months and PFS ranged from 1.0 to 5.6 months, respectively, in the maintenance study of placebo versus regorafenib arms of the REGOSARC trial \[[@B57-cancers-10-00417]\].

Currently no standard approach exists for the use of systemic anti-cancer therapy in SS, neither are there studies that evaluate what sequencing of agents is recommended. An anthracycline plus ifosfamide combination is often considered in the first line treatment as it has a high response rate in STS \[[@B72-cancers-10-00417]\]. However, the recent approval of olaratumab has led to the consideration of doxorubicin in combination with olaratumab as an alternate option in the anthracycline naive setting \[[@B73-cancers-10-00417],[@B74-cancers-10-00417]\]. Treatment decisions tend to be made based on retrospective data and the treating physician and patient preferences to provide the best tumor outcomes and optimize the risk to benefit ratio. Clinical features including age, tumor size and location are also used in selecting an optimal regimen \[[@B14-cancers-10-00417],[@B33-cancers-10-00417]\]. The use of adjuvant/neoadjuvant chemotherapy remains controversial as there are no definitive trials to support its use in practice, and a recent large multicenter histology driven use of neoadjuvant did not show benefit over standard systemic anti-cancer therapy \[[@B51-cancers-10-00417]\]. However, factors associated with receipt of adjuvant chemotherapy were age \<30, primary extremity site, grade 3 histology, tumor size \>5cm and positive surgical margins \[[@B33-cancers-10-00417]\].

5. Conclusions {#sec5-cancers-10-00417}
==============

SS represents 5--10% of all STS; as a result, published literature often does not focus on the specific histology, but rather reports on patients with SS as part of the larger STS group. There is a need to further understand the biology and develop novel therapeutics for this distinct subtype as well as to understand tumor genomics and mechanisms of resistance. Current clinical practice is to treat SS based on evidence from published prospective clinical trials that enrolled multiple subtypes of STS. This SLR has multiple limitations and is not generalizable; but gives an overview of the available data for the use of current systemic anti-cancer therapy options for treatment planning for patients with SS. Additional multi-center and global prospective observational studies and randomized clinical trials to better define the most appropriate treatment for SS in all stages and lines of therapy are still needed. Areas of future research cover a broad range of treatments including targeted therapies e.g., *NY-ESO-1*-directed therapies, tyrosine kinase inhibitors, Adoptive Cell therapies, epigenetics e.g., HDAC and EZH2 inhibitors, chromatin remodeling and metabolic pathways.

The following are available online at <http://www.mdpi.com/2072-6694/10/11/417/s1>, Table S1: Search Strategies implemented in each database, Table S2: Reported objectives of studies included in review.
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CYVADIC

cyclophosphamide, vincristine, doxorubicin, and dacarbazine

Dox + Ifo

doxorubicin + ifosfamide

FNCLCC

Federation Nationale des Centres de Lutte Contre le Cancer

ICD

International statistical Classification of Disease and related health problems

SLR

systematic literature review

SS

synovial sarcoma

STS

soft tissue sarcoma
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###### 

Eligibility criteria.

  ------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------
  **Patients**                    Patients with reported SS (adult or pediatric)
  **Interventions/Comparators**   Systemic anti-cancer therapy
  **Outcomes**                    OS, PFS, response (including overall, complete and partial response and stable and progressive disease), duration of response, time to next treatment
  **Study Design**                Clinical trials (randomized or non-randomized) or observational study, excluding case reports and case series; minimum number of SS patients: 50
  **Geography/Language**          Europe, North America, Japan, Australia or New Zealand; published in English
  **Publication Year**            2000--2018
  ------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------

SS: Synovial Sarcoma, OS: Overall survival, PFS: Progression free survival.
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###### 

Included studies and their characteristics.

  Author, Publication Year                        Country                        Number of Participants   Study Design              Follow-Up in Months Median (Range)
  ----------------------------------------------- ------------------------------ ------------------------ ------------------------- ------------------------------------
  **Localized**                                                                                                                     
  de Silva, 2004 \[[@B31-cancers-10-00417]\]      Scotland                       51                       Retrospective, Cohort     99
  Scheer, 2016 \[[@B37-cancers-10-00417]\]        Germany                        52                       Retrospective, Cohort     \--
  Krieg, 2011 \[[@B38-cancers-10-00417]\]         Switzerland                    62                       Retrospective, Cohort     136.8 (3.6--331.2)
  Beaino, 2016 \[[@B23-cancers-10-00417]\]        USA                            63                       Retrospective, Cohort     85 \* (13--210)
  Orbach, 2011 \[[@B36-cancers-10-00417]\]        Europe                         88                       Retrospective, Cohort     102 (3--168)
  Shi, 2013 \[[@B39-cancers-10-00417]\]           USA                            92                       Retrospective, Cohort     62.4
  Eilber, 2007 \[[@B4-cancers-10-00417]\]         USA                            101                      Retrospective, Cohort     58 (12--185)
  Al-Hussaini, 2011 \[[@B34-cancers-10-00417]\]   Canada                         102                      Retrospective, Cohort     67.2 (3.1--216)
  Trassard, 2001 \[[@B40-cancers-10-00417]\]      France                         128                      Retrospective, Cohort     128
  Ferrari, 2015 \[[@B12-cancers-10-00417]\]       Multi-national                 138                      Prospective trial         52.1 (13.8--104.4)
  Brecht, 2006 \[[@B41-cancers-10-00417]\]        Germany, Italy                 150                      Retrospective, Cohort     80 (6--250)
  Italiano, 2009 \[[@B35-cancers-10-00417]\]      France, Switzerland            237                      Retrospective, Cohort     58 (1--321)
  Canter, 2008 \[[@B42-cancers-10-00417]\]        USA                            255                      Retrospective, Cohort     72 (0--287)
  Vlenterie, 2015 \[[@B43-cancers-10-00417]\]     Netherlands                    461                      Retrospective, Cohort     \--
  Vining, 2017 \[[@B33-cancers-10-00417]\]        USA                            544                      Retrospective, Cohort     49.2
  Gronchi, 2017 \[[@B51-cancers-10-00417]\]       France, Italy, Poland, Spain   70 †                     Prospective trial         12.3
  **Locally advanced or metastatic**                                                                                                
  Takenaka, 2008 \[[@B30-cancers-10-00417]\]      Japan                          108                      Retrospective, Cohort     54
  Setsu, 2013 \[[@B44-cancers-10-00417]\]         Japan                          112                      Retrospective, Cohort     51
  Deshmukh, 2004 \[[@B45-cancers-10-00417]\]      USA                            135                      Retrospective, Cohort     78 (20--420)
  Guillou, 2004 \[[@B29-cancers-10-00417]\]       France, Switzerland, Belgium   165                      Retrospective, Cohort     37 (2--302)
  Palmerini, 2009 \[[@B46-cancers-10-00417]\]     Italy                          250                      Retrospective, Cohort     66
  Ferrari, 2004 \[[@B47-cancers-10-00417]\]       Italy                          271                      Retrospective, Cohort     65 (12--250)
  Vlenterie, 2016 \[[@B28-cancers-10-00417]\]     Europe                         313                      Retrospective, Cohort     \--
  Brennan, 2016 \[[@B11-cancers-10-00417]\]       England                        1318                     Retrospective, Cohort     \--
  Corey, 2014 \[[@B48-cancers-10-00417]\]         USA                            3756                     Retrospective, Database   \--
  Spurrell, 2005 \[[@B25-cancers-10-00417]\]      UK                             104                      Retrospective, Cohort     \--
  **Metastatic disease**                                                                                                            
  Sanfilippo, 2015 \[[@B49-cancers-10-00417]\]    Italy, France, UK              61                       Retrospective, Cohort     \--
  Savina, 2017 \[[@B50-cancers-10-00417]\]        France                         188 †                    Prospective, Cohort       61 (1--300)

Abbreviations: '\--' = Not reported; \* mean reported rather than median; † specifically SS patients.
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###### 

Population characteristics.

  Author, Publication Year                          Subgroup                                                                      N Baseline   Age (Years)        \% Female   Treatments (%)   SS Histology (%)   Primary Tumor Site (%)   Resectable (%)                              
  ------------------------------------------------- ----------------------------------------------------------------------------- ------------ ------------------ ----------- ---------------- ------------------ ------------------------ ---------------- ------ ----- ------ ------ ------
  **Localised**                                                                                                                                                                                                                                                                        
  de Silva, 2004 \[[@B31-cancers-10-00417]\]        All SS patients                                                               51           33 (9--77)         49          25               27                 100                      18               77     92    \--    75     100
  Scheer, 2016 \[[@B37-cancers-10-00417]\]          All SS patients, pediatric and adolescent                                     52           13.9 (0.9--20.9)   46          73               94                 100                      65               33     \--   \--    \--    \--
  Krieg, 2011 \[[@B38-cancers-10-00417]\]           All SS patients                                                               62           \-- (6--82)        58          \--              \--                \--                      56               44     76    \--    \--    \--
  Beaino, 2016 \[[@B23-cancers-10-00417]\]          All SS patients                                                               63           33 (4--74)         59          56               14                 \--                      59               38           17     57     100
  Orbach, 2011 \[[@B36-cancers-10-00417]\]          All SS patients, pediatric and adolescent                                     88           12 (2--17)         47          \--              93                 74                       \--              \--    \--   20     46     \--
                                                    IRS I + Tumor size ≤ 5                                                        17           \--                \--         12               65                 88                       \--              \--    \--   \--    \--    \--
                                                    IRS I + Tumor size \> 5                                                       4            \--                \--         \--              100                100                      \--              \--    \--   \--    \--    \--
                                                    IRS II + Tumor size ≤ 5                                                       16           \--                \--         13               88                 94                       \--              \--    \--   \--    \--    \--
                                                    IRS II + Tumor size \> 5                                                      12           \--                \--         33               92                 92                       \--              \--    \--   \--    \--    \--
                                                    IRS III                                                                       39           \--                \--         56               97                 79                       \--              \--    \--   \--    \--    \--
  Shi, 2013 \[[@B39-cancers-10-00417]\]             All SS patients                                                               92           35.3               50          \--              23                 \--                      \--              \--    \--   24     58     100
  Eilber, 2007 \[[@B4-cancers-10-00417]\]           All SS patients                                                               101          34 (16--75)        51          95               67                 \--                      68               32     \--   30     70     \--
                                                    IFO-based                                                                     68           33 (16--64)        54          97               100                \--                      68               32     \--   37     63     \--
                                                    No chemo                                                                      33           38 (17--75)        46          91               0                  \--                      70               30     \--   15     85     \--
  Al-Hussaini, 2011 \[[@B34-cancers-10-00417]\]     All SS patients                                                               \-           \-                 45          78               25                 100                      \--              \--    \--   27     57     100
                                                    Adult patients                                                                87           37.6 (15--76)      48.3        83               14                 100                      \--              \--    \--   30     60     100
                                                    Pediatric patients                                                            15           14 (0.4--18)       26.7        53               87                 100                      \--              \--    \--   13     33     100
  Trassard, 2001 \[[@B40-cancers-10-00417]\]        All SS patients                                                               128          33 (15--76)        58          80               57                 99                       57               35     76    \--    \--    99.2
  Ferrari, 2015 \[[@B12-cancers-10-00417]\]         All SS patients, pediatric and adolescent                                     138          13.7               44          \--              \--                \--                      \--              \--    \--   \--    \--    \--
                                                    IRS I, tumor \< 5 cm, no chemo                                                24           \--                \--         \--              \--                100                      \--              \--    \--   \--    \--    \--
                                                    IRS 1 tumor \> 5 cm or IRSII, three to six courses of adjuvant chemo and RT   37           \--                \--         \--              \--                \--                      \--              \--    \--   \--    \--    \--
                                                    IRS III or N1 tumor, six courses of chemo, delayed surgery, RT                77           \--                \--         \--              \--                \--                      \--              \--    \--   \--    \--    \--
  Brecht, 2006 \[[@B41-cancers-10-00417]\]          All SS patients, pediatric and adolescent                                     150          12 (1--21)         45          71               97                 51                       41               35     84    \--    \--    50.7
  Italiano, 2009 \[[@B35-cancers-10-00417]\]        All SS patients                                                               237          35 (15--76)        51          \--              \--                100                      \--              \--    \--   21     65     100
  Canter, 2008 \[[@B42-cancers-10-00417]\]          All SS patients                                                               255          34                 50          \--              \--                \--                      66               34     \--   23     58     \--
                                                    SYT-SSX1                                                                      73           41 (16--80)        36          66               47                 \--                      56               44     \--   20     59     \--
                                                    SYT-SSX2                                                                      59           35 (18--78)        63          75               40                 \--                      85               15     \--   19     56     \--
  Vlenterie, 2015 \[[@B43-cancers-10-00417]\]       All SS patients                                                               461          38 (2--89)         46          \--              \--                \--                      22               24     66    \--    \--    90.2
  Vining, 2017 \[[@B33-cancers-10-00417]\]          All SS patients                                                               544          42 (29--55)        49.5        \--              \--                \--                      41.5             22.6   \--   18.4   47.2   100
  Gronchi, 2017\* \[[@B51-cancers-10-00417]\]       SS patients receiving standard chemotherapy                                   36           \--                \--         \--              \--                \--                      \--              \--    \--   \--    \--    100
                                                    SS patients receiving histotype-tailored therapy                              34           \--                \--         \--              \--                \--                      \--              \--    \--   \--    \--    100
  **Mixed population (localized and metastatic)**                                                                                                                                                                                                                                      
  Takenaka, 2008 \[[@B30-cancers-10-00417]\]        All SS patients                                                               108          37 (8--74)         59.3        21               77                 93                       63               30     67    \--    \--    96.3
  Setsu, 2013 \[[@B44-cancers-10-00417]\]           All SS patients                                                               112          \--                61          15               24                 \--                      67               29     \--   \--    \--    \--
  Deshmukh, 2004 \[[@B45-cancers-10-00417]\]        All SS patients                                                               135          31 (8--81)         37          71               38                 90                       \--              \--    \--   16     65     \--
  Palmerini, 2009 \[[@B46-cancers-10-00417]\]       Metastatic                                                                    46           40 (13--79)        39          \--              \--                89                       74               22     \--   \--    \--    \--
                                                    Localized                                                                     204          36 (7--83)         54          \--              48                 100                      60               36     \--   \--    \--    \--
  Ferrari, 2004 \[[@B47-cancers-10-00417]\]         All SS patients                                                               271          32 (5--87)         47          \--              41                 \--                      38               43           22     63     \--
  Vlenterie, 2016 \[[@B28-cancers-10-00417]\]       All SS patients                                                               313          40 (18--81)        39          41               100                43                       \--              \--    56    14     41     \--
  Brennan, 2016 \[[@B11-cancers-10-00417]\]         All SS patients                                                               1318         \--                48          \--              \--                71                       \--              \--    65    \--    \--    \--
                                                    Adults                                                                        1136         \--                48          \--              \--                70                       \--              \--    66    \--    \--    \--
                                                    Children and adolescents                                                      182          \--                43          \--              \--                77                       \--              \--    63    \--    \--    \--
  Corey, 2014 \[[@B48-cancers-10-00417]\]           SS, biphasic                                                                  732          40                 47          \--              \--                \--                      \--              100    \--   \--    \--    \--
                                                    SS, histology not specified                                                   1820         41                 48          \--              \--                \--                      \--              \--    \--   \--    \--    \--
                                                    SS, spindle cell                                                              1204         41                 49          \--              \--                \--                      \--              \--    \--   \--    \--    \--
  Spurrell, 2005 \[[@B25-cancers-10-00417]\]        All SS patients                                                               104          33                 50          67               30                 87                       40               38     66    18     48     \--
  **Metastatic disease**                                                                                                                                                                                                                                                               
  Sanfilippo, 2015 \[[@B49-cancers-10-00417]\]      All SS patients                                                               61           37 (18--68)        58          \--              100                \--                      \--              \--    57    \--    \--    0
  Savina, 2017 \* \[[@B50-cancers-10-00417]\]       All SS patients                                                               188          \--                \--         \--              \--                \--                      \--              \--    \--   \--    \--    \--

Abbreviations: '\--' = Not reported; IFO = Ifosfamide; IRS = Intergroup Rhabdomyosarcoma Staging; SS = Synovial sarcoma. \* baseline characteristics only provided for total STS population.
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###### 

Survival outcomes.

  Study ID                                                       Population                                                                   N          PFS                 OS                                      
  -------------------------------------------------------------- ---------------------------------------------------------------------------- ---------- ------------------- ------------------ -------------------- --------------------
  **Localized**                                                                                                                                                                                                      
  ***Time point 1 year***                                                                                                                                                                                            
  Italiano, 2009 \[[@B35-cancers-10-00417]\]                     All SS patients                                                              237        \--                 \--                85 (82, 88)          136 (70, 204)
  ***Time point 3 years***                                                                                                                                                                                           
  Ferrari, 2015 \[[@B12-cancers-10-00417]\]                      Tumor site-axial                                                             39         77.7 (60.2--88.2)   \--                100 (-)              \--
                                                                 Tumor site-extremities                                                       99         83.8 (74.4--89.9)   \--                96 (88.2--98.7)      \--
  ***Time point 5 years***                                                                                                                                                                                           
  de Silva, 2004 \[[@B31-cancers-10-00417]\]                     All SS patients                                                              51         \--                 \--                56 (-)               40.1 (-)
  Scheer, 2016 \[[@B37-cancers-10-00417]\]                       All SS patients                                                              52         26 (-)              \--                40 (-)               \--
  Tumor site-axial                                               11                                                                           18.2 (-)   \--                 22.7 (-)           \--                  
  Tumor site-non-axial                                           41                                                                           28.4 (-)   \--                 44.7 (-)           \--                  
  Krieg, 2011 \[[@B38-cancers-10-00417]\]                        All SS patients                                                              62         \--                 \--                74.2 (-)             \--
  FNCLCC Grade 2                                                 32                                                                           \--        \--                 97 (-)             \--                  
  FNCLCC Grade 3                                                 11                                                                           \--        \--                 18 (-)             \--                  
  Orbach, 2011 \[[@B36-cancers-10-00417]\]                       All SS patients, pediatric                                                   88         68 (-)              \--                85 (-)               \--
  Shi, 2013 \[[@B39-cancers-10-00417]\]                          All SS patients                                                              92         56 (-)              \--                61 (-)               \--
  Chemo                                                          21                                                                           67 (-)     \--                 65 (-)             \--                  
  No Chemo                                                       71                                                                           49 (-)     \--                 53 (-)             \--                  
  Tumor site-extremities                                         75                                                                           57 (-)     \--                 60 (-)             \--                  
  Tumor site-trunk                                               11                                                                           52 (-)     \--                 63 (-)             \--                  
  Al-Hussaini, 2011 \[[@B34-cancers-10-00417]\]                  All SS patients                                                              102        69.3 (-)            \--                80.3 (-)             \--
  Adult                                                          87                                                                           68.3 (-)   \--                 76.9 (-)           \--                  
  Pediatric                                                      15                                                                           74.9 (-)   \--                 100 (-)            \--                  
  Chemo (all SS patients)                                        25                                                                           62.6 (-)   \--                 \--                \--                  
  No Chemo                                                       77                                                                           71.5 (-)   \--                 \--                \--                  
  Ferrari, 2015 \[[@B12-cancers-10-00417]\]                      All SS patients                                                              138        80.7 (72.5, 86.7)   \--                90.7 (82, 95.3)      \--
  Brecht, 2006 \[[@B41-cancers-10-00417]\]                       All SS patients                                                              150        77 (-)              \--                89 (-)               \--
  Tumor site-extremities                                         129                                                                          79 (-)     \--                 90 (-)             \--                  
  Tumor site-other (not extremities)                             21                                                                           68 (-)     \--                 88 (-)             \--                  
  Tumor status-T1                                                94                                                                           88 (-)     \--                 96 (-)             \--                  
  Italiano, 2009 \[[@B35-cancers-10-00417]\]                     All SS patients                                                              237        \--                 \--                64 (59, 69)          \--
  Vlenterie, 2015 \[[@B43-cancers-10-00417]\]                    All SS patients                                                              461        \--                 \--                63.5 (-)             \--
  Takenaka, 2008 \[[@B30-cancers-10-00417]\]                     Localized                                                                    91         \--                 \--                81 (-)               \--
  Deshmukh, 2004 \[[@B45-cancers-10-00417]\]                     Localized (primary + locally recurrent)                                      108        \--                 \--                69 (-)               \--
  Palmerini, 2009 \[[@B46-cancers-10-00417]\]                    Localized                                                                    204        58 (51, 66)         \--                76 (69, 82)          \--
  ***Time point 9 years***                                                                                                                                                                                           
  Italiano, 2009 \[[@B35-cancers-10-00417]\]                     All SS patients                                                              237        \--                 \--                46 (40, 52)          \--
  ***Time point 10 years***                                                                                                                                                                                          
  de Silva, 2004 \[[@B31-cancers-10-00417]\]                     All SS patients                                                              51         \--                 \--                45 (-)               \--
  Krieg, 2011 \[[@B38-cancers-10-00417]\]                        All SS patients                                                              62         \--                 \--                61.2 (-)             \--
  FNCLCC Grade 2                                                 32                                                                           \--        \--                 84 (-)             \--                  
  FNCLCC Grade 3                                                 11                                                                           \--        \--                 0 (-)              \--                  
  Shi, 2013 \[[@B39-cancers-10-00417]\]                          All SS patients                                                              92         53 (-)              \--                56 (-)               \--
  Chemo                                                          21                                                                           67 (-)     \--                 65 (-)             \--                  
  No Chemo                                                       71                                                                           49 (-)     \--                 48 (-)             \--                  
  Tumor site-extremities                                         75                                                                           55 (-)     \--                 55 (-)             \--                  
  Tumor site-trunk                                               11                                                                           41 (-)     \--                 63 (-)             \--                  
  Brecht, 2006 \[[@B41-cancers-10-00417]\]                       All SS patients                                                              150        89 (-)              \--                78 (-)               \--
  Vlenterie, 2015 \[[@B43-cancers-10-00417]\]                    All SS patients                                                              461        \--                 \--                53.8 (-)             \--
  Deshmukh, 2004 \[[@B45-cancers-10-00417]\]                     All SS patients                                                              108        \--                 \--                51 (-)               
  Localized (primary + locally recurrent)                        108                                                                          \--        \--                 51 (-)             \--                  
  **Mixed population localized/locally advanced / metastatic**                                                                                                                                                       
  ***Time point 2 years***                                                                                                                                                                                           
  Corey, 2014 \[[@B48-cancers-10-00417]\]                        SS, biphasic                                                                 732        \--                 \--                85 (-)               \--
                                                                 SS, NOS                                                                      1820       \--                 \--                71 (-)               \--
                                                                 SS, spindle cell                                                             1204       \--                 \--                77 (-)               \--
  ***Time point 1 year***                                                                                                                                                                                            
  Vlenterie, 2016 \[[@B28-cancers-10-00417]\]                    All SS patients                                                              313        18.7 (14.6, 23.3)   6.3 (5.9, 7.0)     63.7 (57.9, 68.8)    15 (13.9, 16.4)
                                                                 Anthracycline                                                                121        17.5 (11.2, 24.9)   5.06 (4.3, 6.1)    62.6 (53.1, 70.8)    14.85 (12.2, 16.2)
                                                                 Dox + IFO                                                                    112        21.4 (14.4, 29.4)   7.47 (6.5, 8.7)    66.3 (56.7, 74.3)    14.98 (12.9, 18.9)
                                                                 CYVADIC                                                                      30         23.3 (10.3, 39.4)   6.08 (3.0, 10.8)   58.6 (38.7, 74.1)    15.8 (8.4, 23.1)
                                                                 IFO                                                                          42         15.5 (6.4, 28.5)    7.2 (5.9, 9.2)     65.6 (48.9, 78)      15.34 (11.7, 19.7)
                                                                 Other chemotherapy                                                           8          0 (-)               2.27 (1.0, 9.0)    29.2 (1, 71.9)       10.45 (0.9, NR)
                                                                 Tumor site-extremity ^b^                                                     174        16.1 (11--21.9)     6.21 (5.3--7.1)    63.1 (55.3--69.69)   15.5 (13.3--18.1)
                                                                 Tumor site-other ^c^                                                         52         22.0 (11.9--34.2)   7.13 (5.1--8.9)    63.6 (48.6--75.3)    14.4 (11.6--18.7)
  ***Time point 3 years***                                                                                                                                                                                           
  Ferrari, 2015 \[[@B12-cancers-10-00417]\]                      IRS I, tumor \<5 cm, no chemo                                                24         91.7 (70.6, 97.8)   \--                100 (-)              \--
                                                                 IRS 1 tumor \>5 cm or IRSII, three to six courses of adjuvant chemo and RT   37         91.2 (75.1, 97.1)   \--                100 (-)              \--
                                                                 IRS III or N1 tumor, six courses of chemo, delayed surgery, RT               77         77.7 (60.2--88.2)   \--                100 (-)              \--
  ***Time point 5 years***                                                                                                                                                                                           
  Takenaka, 2008 \[[@B30-cancers-10-00417]\]                     All SS patients                                                              108        \--                 \--                69.8 (-)             \--
  Tumor site-extremities                                         72                                                                           \--        \--                 57.4 (-)           \--                  
  Tumor site-trunk                                               36                                                                           \--        \--                 78.1 (-)           \--                  
  Setsu, 2013 \[[@B44-cancers-10-00417]\]                        All SS patients                                                              65         \--                 24 (-)             62 (-)               \--
  Tumor site-distal extremities                                  39                                                                           48.3 (-)   \--                 79.8 (-)           \--                  
  Tumor site-proximal extremities                                63                                                                           36.5 (-)   \--                 50.9 (-)           \--                  
  Deshmukh, 2004 \[[@B45-cancers-10-00417]\]                     All SS patients                                                              135        \--                 \--                61 (-)               \--
  Palmerini, 2009 \[[@B46-cancers-10-00417]\]                    All SS patients                                                              \-         \--                 \--                68 (-)               \--
  Tumor site-lower extremities                                   \-                                                                           59 (-)     \--                 75 (-)             \--                  
  Tumor site-upper extremities                                   \-                                                                           76 (-)     \--                 78 (-)             \--                  
  Ferrari, 2004 \[[@B47-cancers-10-00417]\]                      All SS patients                                                              271        36.8 (-)            \--                64.3 (-)             \--
                                                                 Adjuvant chemo                                                               61         55.3 (-)            \--                71.5 (-)             \--
                                                                 No adjuvant chemo                                                            154        35.2 (-)            \--                70.3 (-)             \--
                                                                 IFO + Dox/Epi                                                                \-         52.3 (-)            \--                \--                  \--
                                                                 Other chemo                                                                  \-         59.4 (-)            \--                \--                  \--
                                                                 Locally advanced disease ^a^                                                 40         31.9 (-)            \--                49.6 (-)             \--
  Corey, 2014 \[[@B48-cancers-10-00417]\]                        SS, biphasic                                                                 732        \--                 \--                65 (-)               \--
                                                                 SS, histology not specified                                                  1820       \--                 \--                52 (-)               \--
                                                                 SS, spindle cell                                                             1204       \--                 \--                56 (-)               \--
  ***Time point 10 years***                                                                                                                                                                                          
  Deshmukh, 2004 \[[@B45-cancers-10-00417]\]                     All SS patients                                                              135        \--                 \--                42 (-)               \--
  Primary tumor                                                  99                                                                           \--        \--                 55 (-)             \--                  
  Local recurrence                                               9                                                                            \--        \--                 11 (-)             \--                  
  Ferrari, 2004 \[[@B47-cancers-10-00417]\]                      All SS patients                                                              271        29.8 (-)            \--                \--                  \--
  ***Time point not reported***                                                                                                                                                                                      
  Spurrell, 2005 \[[@B25-cancers-10-00417]\]                     All SS patients                                                              104        \--                 \--                \--                  22 (-)
  **Metastatic disease**                                                                                                                                                                                             
  ***Time point 0.5 years***                                                                                                                                                                                         
  Sanfilippo, 2015 \[[@B49-cancers-10-00417]\]                   All SS patients                                                              61         23 (-)              3 (-)              \--                  \--
  ***Time point 5 years***                                                                                                                                                                                           
  Takenaka, 2008 \[[@B30-cancers-10-00417]\]                     Metastatic                                                                   17         \--                 \--                0 (-)                
  Palmerini, 2009 \[[@B46-cancers-10-00417]\]                    Metastatic                                                                   46         \--                 \--                10 (-)               \--
  Brecht, 2006 \[[@B41-cancers-10-00417]\]                       Tumor status-T2                                                              53         60 (-)              \--                78 (-)               \--
  Savina 2017 \[[@B50-cancers-10-00417]\]                        Metastatic                                                                   188        7.14 (-)            19.7               \--                  \--
  ***Time point 10 years***                                                                                                                                                                                          
  Deshmukh, 2004 \[[@B45-cancers-10-00417]\]                     Metastatic                                                                   27         \--                 \--                15 (-)               \--

Abbreviations: '\--' = Not reported; CYVADIC = Cyclophosphamide, vincristine, adriamycin and DTIC; Dox + IFO = Doxorubicin and ifosfamide; Ifo + Dox/Epi = Ifosfamide and doxorubicin or epirubicin. ^a^ Considered unresectable at diagnosis; ^b^ Consisting of lower and upper extremities; ^c^ Consisting of trunk, head and neck, abdominal, thorax, gastrointestinal, skin, visceral gynecological, and other.

cancers-10-00417-t005_Table 5

###### 

SS specific PFS and OS data from prospective studies with a cohort \<50 patients.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID                                          Total Cohort (N)   Synovial Sarcoma Cohort (N)   Treatment Arm                                              Progression Free Survival (PFS)   Overall Survival (OS)                                                                     
  ------------------------------------------------- ------------------ ----------------------------- ---------------------------------------------------------- --------------------------------- ------------------------- ------------------- ----- ------------------ ------------------ -------------------
  **Relapse/refractory**                                                                                                                                                                                                                                                                    

  Pappo, 2014 \[[@B52-cancers-10-00417]\]           163                23                            R1507                                                      1.3 (1.2, 1.3)                    \--                       \--                 \--   \--                \--                17

  Sleijfer, 2011\                                   142                38                            Pazopanib                                                  5.3 (2.6, 6.3)                    \--                       \--                 \--   \--                10.2 (7.5, 13.3)   NR
  (EORTC Study 62043) \[[@B53-cancers-10-00417]\]                                                                                                                                                                                                                                           

  **Locally advanced or metastatic**                                                                                                                                                                                                                                                        

  Pappo, 2005 \[[@B54-cancers-10-00417]\]           43                 16                            Neoadjuvant vincristine, ifosfamide, and doxorubicin ^a^   \--                               \--                       \--                 36    56.3 (SD: 12)      \--                81.3 (SD:10)

  **Metastatic disease**                                                                                                                                                                                                                                                                    

  Chugh, 2009 \[[@B55-cancers-10-00417]\]           185                22                            Imatinib                                                   1.92 (1.92, 3.96)                 \--                       \--                 \--   \--                \--                \--

  Kawai, 2015 \[[@B56-cancers-10-00417]\]           76                 7                             Trabectedin                                                NR                                Trabectedin vs. BSC       0.14 (0.03, 0.68)   \--   \--                \--                \--

  Mir, 2016\                                        90                 13                            Regorafenib                                                5.6 (1.4, 11.6)                   Regorafenib vs. placebo   0.10 (0.03, 0.35)   3     77 (42, 92)        13.4 (5.3, NR)     92
  (REGOSARC) \[[@B57-cancers-10-00417]\]                                                                                                                                                                                                                                                    

                                                                                                     Regorafenib                                                \--                               \--                       \--                 6     38 (14, 63)        \--                77

                                                                                                     Regorafenib                                                \--                               \--                       \--                 9     38 (14, 63)        \--                \--

                                                    92                 14                            Placebo                                                    1.0 (0.8, 1.4)                    \--                       \--                 3     0                  6.7 (2.2, NR)      85

                                                                                                     Placebo                                                    \--                               \--                       \--                 6     0                  \--                64

                                                                                                     Placebo                                                    \--                               \--                       \--                 9     0                  \--                \--

  Ray---Coquard, 2008 \[[@B58-cancers-10-00417]\]   48 ^b^             46                            Gefitinib                                                  1.4                               \--                       \--                 \--   \--                                   

  Schoffski, 2011 \[[@B59-cancers-10-00417]\]       128                19                            Eribulin mesylate                                          2.6 (2.3, 4.3)                    \--                       \--                 3     21.1               \--                71.1 (43.7, 86.8)

  Schoffski, 2013 \[[@B60-cancers-10-00417]\]       111                17                            Cixutumumab                                                1.5 (1.3, 2.6)                    \--                       \--                 3     21.4 (5.2, 44.8)   13.0 (5.1, 16.5)   94.1 (65, 99.1)

  Van der Graaf, 2012\                              369                30                            Pazopanib                                                  \--                               SS vs. other STS          0.82 (0.51, 1.32)   \--   \--                \--                \--
  (PALETTE) \[[@B61-cancers-10-00417]\]                                                                                                                                                                                                                                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: '\--' = Not reported; BSC = Best supportive care; EORTC = European Organisation for Research and Treatment of Cancer; IFO + Epi = Ifosfamide and epirubicin; NR = Not reached; SS = Synovial sarcoma; STS = Soft-tissue sarcoma. ^a^ Given with granulocyte stimulating factor; ^b^ was solely a SS cohort, but only 46 evaluable for efficacy endpoint.
